Retatrutide
10 mg
Triple agonist (GLP-1/GIP/glucagon) studied in preclinical and clinical research for its effect on energy balance. Published work describes signaling on appetite-regulating pathways, basal energy expenditure and insulin sensitivity, with observed changes in adipose tissue in study models.
- Studied for thermogenic and lipolytic signaling
- Investigated on appetite-regulating pathways
- Changes observed in visceral and subcutaneous adipose tissue
- Studied for its effect on nutrient partitioning
Scientific context
Origin, mechanism, and research
Developed by Eli Lilly and described in the scientific literature since 2022, Retatrutide (LY3437943) is a synthetic peptide modified with a C20 fatty-acid chain that binds plasma albumin, extending its half-life to roughly 6 days and allowing weekly dosing. It is NOT currently FDA-approved: it is in phase 3 human clinical trials (the TRIUMPH program) for obesity, type 2 diabetes, sleep apnea, osteoarthritis, and fatty liver disease. It simultaneously activates the GLP-1, GIP, and glucagon receptors, with greater potency at GIP; the glucagon component sets it apart from dual agonists like tirzepatide by adding an effect on hepatic energy expenditure.
Information for educational and informational purposes, based on public sources; it does not constitute medical advice. Product for laboratory research use only — not for human consumption.
